July 7, 2006 -- Bayer bought privately held Metrika, which produces a glucose monitoring product; Indevus said the XR version of its overactive bladder drug passed its second Phase III test; CV Therapeutics announced the data safety monitoring board recommended continuing the Phase III trial of Ranexa, BioMarin has begun treating patients in its Phase II test of 6R-BH4, a drug aimed at poorly controlled hypertension; and St. Jude Medical rose on takeover speculation. The Centient Biotech 200™ closed 19 points lower at 3661, a loss of .52%. More details...
